This page contains brief information about melphalan hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Melphalan hydrochloride is approved to treat:
- Multiple myeloma. This use is approved for the Evomela brand of melphalan hydrochloride.
- Uveal melanoma that has spread to the liver and cannot be removed by surgery. It is used in adults whose liver metastases affect less than half of the liver and either the cancer has not spread to other areas of the body or it has spread to the bone, lymph nodes, subcutaneous tissue, or lungs and these metastases can be treated by surgery or radiation therapy. This use is approved for the Hepzato brand of melphalan hydrochloride.
Melphalan hydrochloride is an injection form of melphalan. Melphalan also comes as a tablet that is taken by mouth. For more information about the tablet, see the Drug Information Summary for Melphalan.
Melphalan hydrochloride is also being studied in the treatment of other types of cancer.
More About Melphalan Hydrochloride
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Melphalan Hydrochloride - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Melphalan Hydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.